Miravirsen

• CAT Number: I045367
• CAS Number: 1072874-90-8
• Molecular Weight: 4967.00
• Purity: ≥95%

Miravirsen (Cat No.: I045367) is an investigational antisense oligonucleotide designed to inhibit microRNA-122 (miR-122), a liver-specific microRNA essential for hepatitis C virus (HCV) replication. By binding to and sequestering miR-122, miravirsen disrupts the viral life cycle, reducing HCV RNA levels in infected individuals. It offers a novel, host-targeted antiviral strategy with a high barrier to resistance. Administered via subcutaneous injection, miravirsen has shown promising results in early clinical trials and represents a potential treatment option for chronic HCV infection, especially in resistant cases.

Reference

[1]. Luca F R Gebert, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014 Jan;42(1):609-21.
[Content Brief]

[2]. Elmén J, et, al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008 Mar;36(4):1153-62.
[Content Brief]